当前位置： SCI文献检索 > BMC Medical Genomics期刊下所有文献 > Loss of heterozygosity: what is it good for?

Loss of heterozygosity: what is it good for?

Abstract：

BACKGROUND:Loss of heterozygosity (LOH) is a common genetic event in cancer development, and is known to be involved in the somatic loss of wild-type alleles in many inherited cancer syndromes. The wider involvement of LOH in cancer is assumed to relate to unmasking a somatically mutated tumour suppressor gene through loss of the wild type allele. METHODS:We analysed 86 ovarian carcinomas for mutations in 980 genes selected on the basis of their location in common regions of LOH. RESULTS:We identified 36 significantly mutated genes, but these could only partly account for the quanta of LOH in the samples. Using our own and TCGA data we then evaluated five possible models to explain the selection for non-random accumulation of LOH in ovarian cancer genomes: 1. Classic two-hit hypothesis: high frequency biallelic genetic inactivation of tumour suppressor genes. 2. Epigenetic two-hit hypothesis: biallelic inactivation through methylation and LOH. 3. Multiple alternate-gene biallelic inactivation: low frequency gene disruption. 4. Haplo-insufficiency: Single copy gene disruption. 5. Modified two-hit hypothesis: reduction to homozygosity of low penetrance germline predisposition alleles. We determined that while high-frequency biallelic gene inactivation under model 1 is rare, regions of LOH (particularly copy-number neutral LOH) are enriched for deleterious mutations and increased promoter methylation, while copy-number loss LOH regions are likely to contain under-expressed genes suggestive of haploinsufficiency. Reduction to homozygosity of cancer predisposition SNPs may also play a minor role. CONCLUSION:It is likely that selection for regions of LOH depends on its effect on multiple genes. Selection for copy number neutral LOH may better fit the classic two-hit model whereas selection for copy number loss may be attributed to its effect on multi-gene haploinsufficiency. LOH mapping alone is unlikely to be successful in identifying novel tumour suppressor genes; a combined approach may be more effective.

journal_name

BMC Med Genomics

journal_title

BMC medical genomics

authors

Ryland GL,Doyle MA,Goode D,Boyle SE,Choong DY,Rowley SM,Li J,Australian Ovarian Cancer Study Group.,Bowtell DD,Tothill RW,Campbell IG,Gorringe KL

doi

10.1186/s12920-015-0123-z

subject

Has Abstract

pub_date

2015-08-01 00:00:00

pages

issn

1755-8794

pii

10.1186/s12920-015-0123-z

journal_volume

pub_type

杂志文章

在线工具

Loss of heterozygosity: what is it good for?